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Direct costs of radiotherapy for rectal cancer: a
microcosting study
Paul Hanly1*†, Alan Ó Céilleachair2*†, Máiréad Skally3, Ciaran O’Neill4 and Linda Sharp2
Abstract
Background: Radiotherapy provides significant benefits in terms of reducing risk of local recurrence and death
from rectal cancer. Despite this, up-to-date cost estimates for radiotherapy are lacking, potentially inhibiting policy
and decision-making. Our objective was to generate an up-to-date estimate of the cost of traditional radiotherapy
for rectal cancer and model the impact of a range of potential efficiency improvements.
Methods: Microcosting methods were used to estimate total direct radiotherapy costs for long- (assumed at 45-50 Gy
in 25 daily fractions over a 5 week period) and short-courses (assumed at 25 Gy in 5 daily fractions over a one week
period). Following interviews and on-site visits to radiotherapy departments in two designated cancer centers, a
radiotherapy care pathway for a typical rectal cancer patient was developed. Total direct costs were derived by applying
fixed and variable unit costs to resource use within each care phase. Costs included labor, capital, consumables and
overheads. Sensitivity analyses were performed.
Results: Radiotherapy treatment was estimated to cost between €2,080 (5-fraction course) and €3,609 (25-fraction
course) for an average patient in 2012. Costs were highest in the treatment planning phase for the short-course (€1,217;
58% of total costs), but highest in the radiation treatment phase for the long-course (€1,974: 60% of total costs). By
simultaneously varying treatment time, capacity utilization rates and linear accelerator staff numbers, the base cost
fell by 20% for 5-fractions: (€1,660) and 35% for 25-fractions: (€2,354).
Conclusions: Traditional radiotherapy for rectal cancer is relatively inexpensive. Moreover, significant savings may
be achievable through service organization and provision changes. These results suggest that a strong economic
argument can be made for expanding the use of radiotherapy in rectal cancer treatment.
Keywords: Radiotherapy, Microcosting, Rectal cancer, Efficiency
Background
Colorectal cancer is the third most commonly diagnosed
cancer worldwide with over one million new cases annu-
ally [1]. Around one-third of these cases arise in the rec-
tum. Radiotherapy has been shown to provide significant
benefits in terms of reducing risk of local recurrence and
death from rectal cancer [2]. Despite this, there is evi-
dence that radiotherapy may not be given to as many pa-
tients as could benefit. An Australian study estimated that
more than half of patients with newly diagnosed cancers
could benefit from radiotherapy [3]. Internationally, actual
utilization rates have been shown as lower than this [4-7].
Although underutilized, conventional radiotherapy for
rectal cancer appears to be relatively inexpensive. Five-
year costs for diagnosis and management of a case of
rectal cancer has been estimated to be approximately
€43,000 [8]. In 2008, a course of conventional radiother-
apy for rectal cancer cost was estimated to cost €3,239
[9]. However, this cost was obtained from reviewing
studies from a range of jurisdictions, most of which were
undertaken before or around 2000: no more up-to-date
estimates appear to be available. This lack of up-to-date
cost estimates potentially inhibits policy and decision-
making, and hinders cost-effectiveness comparisons with
various novel radiotherapy treatment strategies which
have been recently developed [10].
We used microcosting methods to generate an up-to-
date estimate of the economic cost of traditional
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radiotherapy treatment for rectal cancer. We also modeled
the impact on costs of a range of potential efficiency
improvements in the provision of radiotherapy.
Methods
The microcosting methodology is a technique that at-
tempts to enumerate and cost all inputs consumed due
to a medical intervention. The method purports to ac-
curately reflect actual economic costs associated with an
intervention and can provide a key input for undertaking
economic evaluations. Using this technique we calculated
total direct costs for an average short-course (assumed at
25 Gy in 5 daily fractions over a one week period) and an
average long-course (assumed at 45-50 Gy in 25 daily
fractions over a 5 week period) of radiotherapy for rectal
cancer across different phases of care (as outlined below).
Costs are reported from the perspective of the radiotherapy
department in 2012 euros.
Setting
The study was conducted in Ireland, which has a mixed
public-private healthcare system. All citizens are entitled
to treatment in the public system and the majority make
modest co-payments for overnight hospital stays or out-
patient appointments. Public cancer services are pro-
vided in eight designated cancer centers which operate
within Managed Cancer Control Networks.
Ethics statement
This study has been approved by the appropriate hos-
pital ethics committees. No identifiable human data were
used for this study.
Data collection and phases of care
Data collection involved structured interviews by two of
the authors with senior management and clinical staff in
the radiotherapy units of two designated cancer centers
during 2010 and 2011. In total, three interviews were
undertaken with: a radiation oncologist, a radiotherapy
services manager and a colorectal nurse specialist. The
interview schedule was devised from review of the
microcosting literature [11-15] and previous author in-
terviews with colorectal cancer clinicians (which focused
on treatment options). On-site direct observation was
also undertaken supplemented by follow-up discussions
with the radiology team to appraise any additional items
that required clarification. On-site observation included
visual confirmation of personnel in attendance during
treatment, appraisal of capital equipment employed, and
confirmation of consumables used.
A pathway of care for an “average” (typical) rectal can-
cer patient was subsequently developed encompassing
three “phases”: treatment planning; radiation treatment;
and follow-up.
Cost calculation
Total direct costs were derived by applying unit costs to
resource use within each phase of care. Resource use
was identified in natural units (Table 1) across four
broad components: labor (time), capital (equipment and
maintenance), consumables and overheads. To compute
total costs, we aggregated ‘fixed’ planning and follow-up
costs (these costs did not vary on a fraction basis and
thus were considered ‘fixed’) and ‘variable’ treatment
costs (per fraction) for long- and short-course radiother-
apy treatment. Estimates for a 21 fractions course are
also provided for completeness. For example, the fixed
cost for a long course of treatment was €1,217.2. The
variable treatment cost was €90.9 per fraction. Over a
long course this amounted to €2,272.5 (€90.9*25). Follow
up costs were a fixed sum of €119.2 per patient. The
aggregated total of the three care phases for 25 fractions
was €3,608.9.
Labor costs included the time allocated to radiother-
apy services by all relevant personnel. Time costs were
calculated on a per minute basis initially, and then
multiplied by the time allocated to each procedure for
an average patient to determine per procedure costs.
Salary scales per annum for relevant personnel was con-
verted to a per minute rate by dividing by the number of
workable minutes per year. We assumed a 48 week
working year and a 35 hour working week for all staff
with the exception of radiation oncologists (where we
assumed a 37 hour working week). In addition consum-
ables included the costs of fixation devices or shielding
blocks for certain patients.
The cost of capital was annuitized over its expected
useful economic life using the equivalent annual cost
method [16]. Purchase prices for equipment were ob-
tained from the two hospitals and anticipated life expect-
ancy was set at 10 years. Equipment was assumed to
operate at 100% capacity and costs were discounted at
4% per annum [17]. An estimate for molding equipment
was taken from Kesteloot, Lievens, and van der Schue-
ren [12] and updated to current prices, using an Irish
health CPI (Central Statistics Office Ireland). Equivalent
annual costs were divided by the number of workable
minutes per year (assuming a 50 week working year and
a 40 hour working week) to derive per minute equip-
ment costs. Per procedure costs were estimated similar
to labor costs. Equipment repair and maintenance costs
were based on hospital budget costs. Building costs were
not included.
Overheads were valued at 40% of the total direct sal-
ary of each relevant staff member following Irish Health
Technology Assessment Guidelines [17]. These costs
were assumed to cover accommodation, utilities (light,
heat and telephone), support and back-office staff and
training.
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Efficiency and sensitivity analyses
In sensitivity analyses we varied the following parame-
ters in a univariate fashion based on suggestions made
by interviewees: time per radiotherapy session, capacity
utilization rates, linear accelerator staff numbers and
overheads. The potential for efficiency improvements
was assessed by simultaneously altering three parameters
as follows: treatment time of 10 minutes compared to
15 minutes in current practice, capacity utilization rates
of 125% (based on proposals for extensions to the stand-
ard working day of radiotherapy units) compared to
100% of the current working day for labor and capital
and three linear accelerator staff compared to the current
practice of four.
Results
Resource use and per minute costs
Resource use and unit costs for each cost category in
each phase of care is presented in Table 1. During the
treatment planning phase, the largest single cost item on
a per procedure basis was the cost of dosimetrist ser-
vices (€285). The highest cost per procedure in the
treatment phase was the cost of the linear accelerator
(€31.50). Labor costs dominated costs in the follow-up
phase.
Radiotherapy costs per fraction
In total, the ‘fixed’ treatment planning costs for a course
of radiotherapy amounted to €1,217 (Table 2). Labor
was the largest driver accounting for 41% of this total,
with much of the labor cost generated by dosimetrist
services. Other imaging services and tests accounted for
a further 37% of total costs, with overheads accounting
for 16% and capital for 6%.
Treatment costs per fraction were estimated at €92
per patient per 25 fraction course (Table 2), €94 per pa-
tient per 21 fraction course and €154 per patient per 5
fraction course. Capital (35%) and labor (33%) generated
over two-thirds of the 25 fraction total. The proportion
of total costs accounted for by capital and labor for a 5
fraction course is somewhat less (57%).
In the follow-up phase, total ‘fixed’ costs were €93 per
patient, with more than 70% of this accounted for by
labor costs and the remainder by overheads.
Table 1 Unit costs (€ 2012) for radiotherapy care resource use by phase of care (25 fraction course)
Phase Cost category Description No. of
units
Cost per unit
per minute (€)
Cost per
procedure (€)
Treatment planning Capital CT simulation and linear accelerator 1 2.10 62.9
Moulding equipment 1 0.26 7.9
Salary Radiation therapist 2 0.44 26.2
Clinical specialist radiographer 2 0.54 32.4
Dosimetrist 2 0.61 285.1
Physicist 1 0.52 31.3
Staff nurse 1 0.37 22.3
Radiation oncologist 1 1.65 66.0
Dietician 1 0.43 12.9
Overheads Simulation - - 23.4
Care plan - - 126.5
Medical work-up - - 47.5
Other
Blood test - - 17.0
Additional imaging - - 438.0
Treatment Capital Linear accelerator 1 2.10 31.4
Moulding equipment 1 0.26 3.0
Salary Radiation therapist 2 0.44 13.1
Clinical specialist radiographer 2 0.54 16.2
Radiation oncologist/Registrar 1 1.10 3.3
Overheads General - - 13.0
Consumables Fixation devices or shielding blocks for a proportion of patients - - 10.9
Follow-up Salary Radiation oncologist/Registrar - 1.10 22.1
Overheads General - - 8.8
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Radiotherapy costs per short- and long-course
A long-course of radiotherapy treatment was esti-
mated to cost €3,609 for 25 fractions (€3,284 for 21
fractions). For an average 25 fraction patient, the
majority of costs were accrued in the treatment phase
(60%); 37% of costs were accrued in the planning
phase and the remaining 3% during follow-up. Short-
course estimates (5 fractions) were €2,080. In this in-
stance, planning phase costs dominated accounting for
59% of the total.
Sensitivity and efficiency analyses
Varying treatment time from 15 minutes (base case)
to 10 minutes caused the total cost per course to fall
by 6% (5 fractions) - 18% (25 fractions); when it was
increased to 20 minutes, the total cost rose by be-
tween 6% and 18% (Figure 1a). Changing capacity
utilization from 100% to 80% caused the base case es-
timate to increase by 16%-19%; increasing utilization
to 125% reduced the total cost by 13-15% across
courses (Figure 1b). The total radiotherapy cost was
Table 2 Per patient and per fraction radiotherapy treatment (25 fractions) costs (€ 2012)
Type Treatment planning % Treatment % Follow-up %
Fixed costs: Cost (€) per patient* Variable costs: Cost (€)
per fraction per patient
Fixed costs:
Cost (€) per patient*
Capital 62.9 5.8 34.4 38.5 0.0 0.0
Labour 493.6 40.6 32.6 35.5 66.3 71.4
Overheads 197.4 16.2 13.0 14.2 26.5 28.6
Other/consumables 455.3 37.4 10.9 11.8 0.0 0.0
Total 1,217.2 90.9 92.8
*Treatment planning costs and follow-up costs are the same irrespective of the length of course.
Figure 1 Sensitivity analysis of key radiotherapy cost drivers: total costs per course and percentage deviation from base case estimates
(in brackets), by number of fractions per course (2012€). a. variations in treatment time (Treatment time refers to the time taken per
radiotherapy session per procedure. 15 minutes relates to current practice). b. variations in capacity utilization (Capacity utilization refers to the time
both labor and capital operate in the radiotherapy department on a given day. 100% relates to current working hours). c. variations in staff
numbers (Staff numbers refers to the number of personnel per linear accelerator per procedure. Four staff members per linear accelerator
relates to current practice). d. variations in overheads (Overheads refers to the costs of accommodation, utilities (light, heat and telephone),
support and back-office staff and training for radiotherapy. 40% relates to Irish current recommendations on the costing of overheads in relation
to direct salary costs).
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relatively insensitive to changes in linear accelerator
staff numbers and overhead costs (Figure 1c and d).
Combined incremental variation of treatment time (to
10 minutes), capacity utilization (to 125%) and linear ac-
celerator staff numbers (to 3) resulted in a decrease in
the base case estimate of total costs for long-course
radiotherapy (25 fractions) of 35%, from €3,609 to €2,354
(Figure 2a). For short-courses, these changes would re-
duce the estimate of total cost per course by 20%, from
€2,080 to €1,660 (Figure 2b).
Discussion
Costing framework and transferability
Our study attempted to address some of the criticisms
made of previous radiotherapy costing studies [9,18].
Previous rectal cancer radiotherapy cost estimates vary
widely, and a lack of transparency in reporting makes it
difficult to explain these differences [9]. We took a “sur-
vey-based” microcosting approach, which has been used
successfully in the past for the costing of various health-
care interventions [15,19]. By interviewing department
managers, clinicians and other staff, we were able to de-
fine a typical care pathway for an average patient. Each
separate process and resource within the pathway was
delineated and apportioned a unit cost. This approach
provided a clear framework for presenting results and
the separate reporting of unit costs should further in-
crease the comparability of the study [15]. The presenta-
tion of unit costs also ensures that estimates can be
altered with country-specific data in other settings. Costs
per fraction, and costs per course, were presented inde-
pendently to allow future investigators, policy makers or
planners to use or synthesis these as required. Overall,
this standardized framework should enhance the trans-
ferability of our results to different settings.
Radiotherapy treatment costs and components
The average cost per course in 2012 was €2,080, €3,284
and €3,609 for 5, 21 and 25 fractions respectively. Our
estimate for a 21 fraction course is slightly higher than
the average cost calculated by Ploquin and Dunscombe
[9] (mean normalized cost in 2005, €3,239). It is impossible
Figure 2 The impact of efficiency gains on the costs of radiotherapy (€) with percentage deviation from base case costs in brackets. a. 25 fraction
course (Each nodal point represents the accumulated cost reduction resulting from the previous efficiency gains). b. 5 fraction course.
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to be entirely certain what costs were included and ex-
cluded from previous studies due to a paucity of presented
detail, however comparisons across broad cost components
can be made.
Unsurprisingly, in our study, labor costs were a key
cost driver, accounting for between 36% and 41% of total
costs incurred during the planning and treatment phases.
This result is relatively consistent throughout the radio-
therapy costing literature where labor costs commonly
account for roughly half of the costs of radiotherapy treat-
ment [12,14]. Capital costs represented 26% of the cost for
a 25 fraction course and were most significant during the
treatment phase, consistent with the findings of previous
radiotherapy costing studies [12,14]. Where our results
differed from others was that overheads accounted for a
higher proportion of total costs in our study. Although
recommended in Ireland [17] the derivation of overhead
costs based on a specific percentage of labor costs is not
standard practice in other countries and may account for
the difference. Nevertheless, the total cost estimate was
relatively insensitive to variations in overheads.
Potential cost savings
Through “efficiency analyses”, informed by expert opin-
ion from our interviews, we were able to highlight key
process areas in which efficiencies might be accrued by
changing current service provision practices. These areas
included: time taken per radiotherapy treatment proced-
ure, capital utilization rates and the number of staff re-
quired per linear accelerator. While our results relate to
practice in Ireland, similar service provision changes
have been proposed in other healthcare systems.
Initially we assumed that an average treatment session
could be cut from 15 to 10 minutes, resulting in a reduc-
tion of almost one-fifth in the total cost of long-course
radiotherapy. An estimate of 10 minutes is consistent
with best practice in Irish cancer centers (interview find-
ing). It is however, possible that reducing procedure time
could impact negatively on quality or, patient satisfac-
tion, or increase the proportion of complicated cases,
but we are not aware of any evidence in this regard.
A further amendment that has been discussed in
Ireland is the extension of service hours. To reflect this,
we assumed an increase in capacity of 25%, which effect-
ively represents an extension of radiotherapy department
operating hours from 9 am–5 pm to 8 am–6 pm. This
change alone resulted in a reduction in total cost per
course of up to one-quarter. However extension of the
treatment day possesses both advantages and disadvan-
tages which have been investigated across Irish, Dutch
and UK radiotherapy treatment departments [20]. While
increasing patient throughput and access, extended
hours could have other consequences, including changes
to shift work systems and flexible working arrangements,
which may cause industrial relations issues. Health and
safety issues would also require monitoring and there
could be a knock-on effect on the working life of linear
accelerators.
Currently, radiotherapy departments in Ireland operate
with four personnel per linear accelerator similar to the
staffing arrangements in the Netherlands, the UK and
Australia [20]. Reducing the number to three could re-
sult in a reduction of costs of up to 9%. However, such a
restructuring would run counter to current recommen-
dations in the recent Report of the Expert Group on
Radiography Grades in Ireland [21], and would require
monitoring to ensure that standards are maintained and
the quality of treatment does not suffer. A further poten-
tial efficiency improvement relates to the mix of staff
present at a radiotherapy treatment session. The use of
staff members at lower pay grades would result in lower
labor costs. However as this measure was not suggested
by any of our interviewees, we chose not to model it.
Cost savings between 20% (short-course) and 35%
(long-course) were derived based on the incremental
adoption of three potential efficiency enhancing changes.
We would argue that these results represent feasible cost
reductions across a range of areas in treatment provision
and would further enhance the appeal of radiotherapy as
a treatment option in rectal cancer. Nevertheless, key
concerns such as potential industrial relations issues and
impacts on quality would require further investigation
(and clarification) before proceeding with these measures.
Strengths and limitations
This study provides an up-to-date estimate of the cost of
standard radiotherapy for rectal cancer which is of value
in its own right for service planning and management
and could be used as a comparator for evaluations of
more novel radiotherapy approaches.
The study has several limitations. Data on resource
use to populate the patient pathways were obtained from
two public hospitals, but there is little reason to believe
that these are not typical of the 8 designated cancer cen-
ters in Ireland. However, private hospital radiotherapy
treatment provision may differ in terms of organization
and practice. Our use of expert interviews and the com-
pilation of resource use for an ‘average’ radiotherapy pa-
tient necessarily limits the detail in the results compared
to, for example, a review of individual patient records or
costs derived from the direct observation of actual re-
source utilization during treatment for individual pa-
tients. Nevertheless, using samples of patient records
can lead to biases in the estimates due to outlier cases
which often skew the results when the sample size is
small [15], while direct observation is extremely resource
intensive and normally requires additional supplementary
consultation and/or interview with hospital departments
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to collect supplementary data. An overview of existing
techniques for microcosting studies is provided by Frick.
Our sole focus was to estimate direct costs from the
perspective of the radiotherapy department; we did not
attempt to calculate indirect costs, or patient out-of-
pocket costs. Our estimates do not include the capital
costs of buildings, due to a lack of information available
at the surveyed institutions. Furthermore, overhead costs
were allocated based on a proportion of labor costs.
Overhead costs, more than any other cost component,
tends to be location and center specific and so their
transferability is generally limited anyway. Finally we did
not attempt to model the impact of patients who cancel
appointments or do not attend for treatment.
Conclusion
Using microcosting methods, we estimated that the total
cost of traditional radiotherapy for rectal cancer in 2012
was €2,080 for an average short-course patient and
€3,284 and €3,609 for an average long-course patient (21
fractions and 25 fractions respectively). Labor was a sig-
nificant cost driver. Significant savings are potentially
achievable through changes in service organization and
provision. Given the effectiveness of radiotherapy in treat-
ing rectal cancer, and it’s relatively low cost compared to
other cancer treatments, a strong argument can be made
for expanding utilization of radiotherapy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PH and AOC contributed to the conception and design of the study, the
acquisition of primary data, the calculation of costs using the microcosting
approach and the interpretation of the results. MS, CON and LS contributed
to the conception and design of the study and the interpretation of the
results. All authors were involved in drafting and revising the article, all have
read and approved the final manuscript and all agree to be accountable for
all aspects of the work.
Acknowledgements
This study was funded by the Health Research Board (Ireland) as part of a
research programme examining the economic impact of cancer in Ireland
(SA/2004/1). We are grateful to the individuals who took part in the
interviews and facilitated on site visits.
Author details
1School of Business, National College of Ireland, Dublin, Ireland. 2Research
Department, National Cancer Registry Ireland, Cork, Ireland. 3Department of
Clinical Microbiology, Beaumont Hospital, Dublin, Ireland. 4J.E. Cairnes School
of Business and Economics, National University of Ireland, Galway, Ireland.
Received: 21 February 2014 Accepted: 24 April 2015
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer.
2010;127:2893–917.
2. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal
cancer: A systematic overview of 8,507 patients from 22 randomised trials.
Lancet. 2001;358:1291–304.
3. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in
cancer treatment: Estimating optimal utilization from a review of evidence-
based clinical guidelines. Cancer. 2005;104:1129–37.
4. National Cancer Registry Ireland. Cancer in Ireland: Annual report of the
National Cancer Registry. 2011. [http://www.ncri.ie/publications/annual-
statistical-reports/cancer-ireland-2011]
5. National Cancer Registry Ireland. Cancer trends no 9. Cancers of colon,
rectosigmoid junction and rectum 2011. [http://www.ncri.ie/publications/
cancer-trends-and-projections/cancer-trends-cancers-colon-and-rectum]
6. Williams MV, Drinkwater KJ. Radiotherapy in England in 2007: Modelled
demand and audited activity. Clin Oncol (R Coll Radiol). 2009;21:575–90.
7. Landrum MB, Keating NL, Lamont EB, Bozeman SR, McNeil BJ. Reasons for
underuse of recommended therapies for colorectal and lung cancer in the
veterans health administration. Cancer. 2012;118:3345–55.
8. Tilson L, Sharp L, Usher C, Walsh C, Whyte S, O'Ceilleachair A, et al. Cost of
care for colorectal cancer in Ireland: A health care payer perspective. Eur J
Health Econ. 2012;13:511–24.
9. Ploquin NP, Dunscombe PB. The cost of radiation therapy. Radiother Oncol.
2008;86:217–23.
10. Van de Werf E, Verstraete J, Lievens Y. The cost of radiotherapy in a decade
of technology evolution. Radiother Oncol. 2012;102:148–53.
11. Dunscombe P, Roberts G, Walker J. The cost of radiotherapy as a function of
facility size and hours of operation. Br J Radiol. 1999;72:598–603.
12. Kesteloot K, Lievens Y, van der Schueren E. Improved management of
radiotherapy departments through accurate cost data. Radiother Oncol.
2000;55:251–62.
13. Lievens Y, van den Bogaert W, Kesteloot K. Activity-based costing: A practical
model for cost calculation in radiotherapy. Int J Radiat Oncol Biol Phys.
2003;57:522–35.
14. Norlund A. SBU Survey Group. Costs of radiotherapy Acta Oncol.
2003;42:411–5.
15. Frick KD. Microcosting quantity data collection methods. Med Care.
2009;47:S76–81.
16. Drummond M, Sculpher M, Torrance G, O'Brien, BJ, Stoddart, GL. Methods
for the economic evaluation of healthcare programmes. 3rd Edn. Oxford
University Press. 2005.
17. Health Information and Quality Authority. Guidelines for the economic
evaluation of health technologies in Ireland. 2010. [http://www.hiqa.ie/
publication/guidelines-economic-evaluation-health-technologies-ireland]
18. Goddard MK, Hutton J. What is the cost of radiotherapy? Eur J Radiol.
1991;13:76–9.
19. Griffith GL, Tudor-Edwards R, Gray J, Butler R, Wilkinson C, Turner J et al. A
micro costing of NHS cancer genetic services. Br J Cancer. 2005;92:60–71.
20. Department of Health. The development of radiation oncology services in
Ireland. 2003. [http://www.hse.ie/eng/services/list/5/cancer/pubs/reports/
Development_of_Radiation_Oncology_in_Ireland.pdf]
21. Department of Health. Report of the expert group on radiography grades.
July, 2001. [http://www.lenus.ie/hse/handle/10147/42528]
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hanly et al. BMC Health Services Research  (2015) 15:184 Page 7 of 7
